Servier Canada
TIBSOVO®
PrTIBSOVO® (ivosidenib)

Patient Profiles

Meet Priya* — a patient with newly diagnosed AML with an IDH1 R132 mutation

Initial presentation1

  • 78-year-old Priya* presented two months ago with significant fatigue
  • Blood tests were abnormal and bone marrow biopsy was performed
  • Diagnosis of AML was confirmed one month ago
  • Mutation testing revealed an IDH1 R132 mutation
  • She has profound anemia that seriously limits her daily activities, and so has been assessed as ECOG PS 2
  • Due to her age and ECOG status, her physician deemed her ineligible for intensive induction chemotherapy

Treatment plan1

  • Priya*’s doctor initiated treatment with TIBSOVO® combined with azacitidine.
  • ECG was performed before treatment initiation, then weekly during the first three weeks and monthly thereafter to monitor for potential QTc prolongation.
  • Priya* was educated on the signs and symptoms of differentiation syndrome and the need to report them immediately to her care team.
Photograph of Priya*, a 78-year-old woman.

Think about TIBSOVO® in combination with azacitidine for your patients like Priya*

*Fictitious patient. May not be representative of all patients.

2-HG: 2-hydroxyglutarate; α-KG: alpha-ketoglutarate; AML: acute myeloid leukemia; AZA: azacitidine; PBO: placebo; CCA: cholangiocarcinoma; CI: confidence interval; CR: complete response; CRh: complete response with partial hematologic recovery; CTCAE: Common Terminology Criteria for Adverse Events; DLCO: diffusing capacity for carbon monoxide; ECG: electrocardiogram; ECOG PS: Eastern Cooperative Oncology Group Performance Status; EFS: event-free survival; eGFR: estimated glomerular filtration rate; FEV1: forced expiratory volume in 1 second; HR: hazard ratio; IDH1: isocitrate dehydrogenase-1; IRC: Independent Radiology Centre; IV: intravenous; mIDH1: mutated isocitrate dehydrogenase-1; MOA: mechanism of action; NCCN: National Comprehensive Cancer Network; OR: odds ratio; OS: overall survival; PBO: placebo; PCR: polymerase chain reaction; PD: pharmacodynamics; PK: pharmacokinetics; QD: daily; RECIST: Response Evaluation Criteria In Solid Tumors; SC: subcutaneous.

References:

  1. TIBSOVO® Product Monograph. Servier Canada. July 19, 2024.
  2. Montesinos P, et al. N Engl J Med. 2022 Apr 21;386(16):1519–1531.
  3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia Version 2.2025 — January 27, 2025.
  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Biliary Duct Cancers Version 6.2024 — January 10, 2025.
  5. Abou-Alfa GK, et al. Lancet Oncol. 2020 Jun;21(6):796-807.
  6. Zhu AX, et al. JAMA Oncol. 2021 Nov 1;7(11):1669-1677.
  7. Dammacco F, Silvestris F, eds. Oncogenomics: From Basic Research to Precision Medicine. Academic Press; 2019.
Back to top

Stay Connected with Servier Canada

Stay up to date on disease information, treatment options, our products, and patient support programs.

Sign Up